Which Companies Will Be Making the News in 2024?

Which companies will be making the news this year—from manufacturing expansions, to mergers & acquisitions, to other key strategic developments? Be among the newsmakers at The DCAT Member Company Announcement Forum at DCAT Week. Applications close Monday February 5.

Which companies will be making the news this year—from manufacturing expansions, to mergers & acquisitions, to other key strategic developments? Be among the newsmakers at The DCAT Member Company Announcement Forum at DCAT Week. Applications close Monday February 5.

Getting the latest news at DCAT Week
Kicking off DCAT Week, the flagship event of the Drug, Chemical & Associated Technologies Association (DCAT) and the premier industry event for companies engaged in bio/pharmaceutical development and manufacturing, the DCAT Member Company Announcement Forum is a much-anticipated program in which senior executives from DCAT Member Companies highlight major news from their companies most impactful to the global bio/pharmaceutical manufacturing value chain.

The program is where the industry gathers to hear about the latest manufacturing expansions across all segments: chemicals/chemical active pharmaceutical ingredient (API) manufacturing, biomanufacturing, drug-product manufacturing, and packaging. It is an opportunity to get the details on the capacity being added, when it is coming on line, and the levels of investment behind those expansions.

It is also where the industry comes to get an inside take on the latest in mergers and acquisitions (M&A) from the deal-makers themselves. Senior executives explain their companies’ strategic rationale behind their moves to build critical mass and the details behind those moves: updates on deal closure and post-M&A integration.  

The program is open to all DCAT Member Companies—bio/pharma companies, CDMOs/CMOs, and other suppliers—but companies must apply to be considered for a presentation slot for this prominent event and much sought-after podium time. 

Applications are closing Monday February 5, 2024. The DCAT Member Company Announcement Forum Oversight Committee will then select companies given podium time based on news priority and interest to DCAT Member Companies. A company’s news must be from 2024 and can involve a merger or acquisition, manufacturing expansion, or other major corporate strategic development. Content criteria and online applications can be found here.

Due to popular demand and the number of applications received, this year’s Forum has been expanded and will be held from 9:00 to 11:30 AM on Monday March 18, 2024. Companies of all sizes—large-, medium-, and small-sized companies—may apply to highlight announcements of importance to the industry. But presentation slots are limited, and applications must be received no later than Monday February 5, 2024.

Need examples of past announcements? Check out the companies that made the news at DCAT Week 2023.

Expect a full house and standing room only of DCAT Week’s influential attendees of senior to mid-level executives to be at the program. The DCAT Member Company Announcement Forum will be held at DCAT Week on Monday, March 18, 2024, from 9:00 to 11:30 AM, at the InterContinental Barclay, Grand Ballroom, in New York. Interested in attending? Click here for further information, including how to register to attend.    

Recent Feature Articles

Industry Roundtable: Small-Molecule APIs: What’s in Store for 2026? 

By
What are the pressing issues shaping the market for fine chemicals and pharma ingredients in 2026—the challenges and the opportunities? Senior executives from CDMOs share their perspectives.  

EU Advances Critical Medicines Act for Securing EU API Supply

By
The European Parliament has endorsed its position on the Critical Medicines Act, setting the stage to finalize the law to assure security of supply for essential medicines in the EU.

CDMO/CMO Outlook: 2026 in Bio/Pharma Outsourcing

By
What can CDMOs/CMOs expect in 2026? DCAT Value Chain Insights looks at the issues shaping the market for bio/pharmaceutical outsourcing in the coming year: key trends, fundamentals, and the variables influencing the sector’s performance.

The DCAT Pulse: The Tariff Outlook & Pharma

By
Evolving US tariff policy is a key variable in the cost structures, manufacturing strategies, and supply chains of bio/pharma companies and their suppliers. A DCAT webinar gives an executive briefing…